このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma

Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial

This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity musculoskeletal sarcoma undergoing en-bloc surgical treatment.

Biopsy tract resection is traditionally recommended to reduce the risk of tumor seeding; however, its benefit in reducing recurrence has not been definitively demonstrated, particularly when core needle biopsy is widely used. Also, avoiding biopsy tract resection may preserve uninvolved tissue without compromising oncologic safety.

The primary objective of this study is to compare local recurrence rates between patients who undergo biopsy tract resection and those who do not. Secondary objectives include comparisons of surgical complications, functional outcomes, overall survival, and progression-free survival.

調査の概要

状態

まだ募集していません

条件

研究の種類

介入

入学 (推定)

3300

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Zhejiang
      • Hangzhou、Zhejiang、中国
        • Hangzhou Third People's Hospital
        • コンタクト:
      • Hangzhou、Zhejiang、中国、311200
        • The Second Affiliated Hospital of Zhejiang University School of Medicine
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  1. Histologically confirmed diagnosis of primary bone or soft tissue sarcoma of the extremities (or highly suspected sarcoma);
  2. Candidate for limb-sparing surgery and capable of en-bloc resection;
  3. Age ≥ 5 years;
  4. ECOG performance status 0-2;
  5. Able to understand and sign informed consent.

Exclusion Criteria:

  1. Presence of distant metastasis (e.g., lung, bone, or other sites) or unresectable skip lesions;
  2. Patients deemed, based on preoperative multidisciplinary team (MDT) evaluation, unlikely to achieve adequate surgical margins and therefore only eligible for debulking or palliative surgery;
  3. Patients with inconclusive needle biopsy results requiring open biopsy for definitive diagnosis;
  4. Patients requiring amputation;
  5. Patients who have received prior treatment for the tumor at non-participating centers;
  6. Patients with an expected survival of less than 2 years;
  7. Patients in whom the biopsy tract completely lies within the planned tumor resection field;
  8. Patients who refuse to provide written informed consent.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:tract resection group

Surgeons will perform standard en-bloc tumor resection according to oncologic principles. In the biopsy tract resection group, complete biopsy tract excision is defined as en-bloc removal of the entire needle biopsy pathway, including:

Skin entry site: the original puncture site on the skin surface Subcutaneous and soft tissue tract: all intervening tissues traversed by the biopsy needle Deep tract structures: any muscle, fascia, periosteum, or bone structures penetrated by the needle Intratumoral component: the terminal segment of the needle pathway within the tumor

All components of the biopsy tract must be removed together with the tumor specimen.

アクティブコンパレータ:tract non-section group

Surgeons will perform standard en bloc tumor resection in accordance with oncologic principles. In the non-resection group, the needle biopsy tract will not be intentionally excised. The biopsy tract, including the skin entry site and intervening soft tissue pathway, will be preserved unless it lies within the planned tumor resection field.

If any portion of the biopsy tract is located within the standard oncologic resection field required to achieve negative margins, it will be removed as part of the tumor specimen; however, no additional resection will be performed specifically to excise the biopsy tract.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Cumulative incidence of local recurrence at 2 years
時間枠:From the date of surgery to the date of first documented local recurrence, death, or last follow-up, assessed up to 24 months after surgery.
Local recurrence is defined as radiologically or pathologically confirmed recurrence of sarcoma at or adjacent to the primary surgical site after definitive tumor resection. The cumulative incidence of local recurrence will be estimated with death treated as a competing event.
From the date of surgery to the date of first documented local recurrence, death, or last follow-up, assessed up to 24 months after surgery.

二次結果の測定

結果測定
メジャーの説明
時間枠
Musculoskeletal Tumor Society score
時間枠:recorded at baseline and at 3, 6, 9, 12, 15, 18, 21, and 24 months after surgery.
MSTS assesses 6 aspects of a patient's quality including pain, function, emotional, supports, walking and gait with regard to their treatment. higher score. The score ranges from 0% (worst function) to 100% (best function). It is a repeated continuous outcome.
recorded at baseline and at 3, 6, 9, 12, 15, 18, 21, and 24 months after surgery.
Henderson failure mode
時間枠:From surgery to 24 months, assessed every 3 months
Henderson failure mode defined as : soft-tissue failure (Type 1), aseptic loosening (Type 2), structural failure (Type 3), infection (Type 4), and tumor progression (Type 5).
From surgery to 24 months, assessed every 3 months
The Patient and Observer Scar Assessment Scale
時間枠:From surgery to 24 months, assessed every 3 months
The Patient and Observer Scar Assessment Scale (POSAS) questionnare is used to evaluate scar quality from both the patient's and the observer's perspectives. Each scale consists of six items, with each item scored from 1 (normal skin) to 10 (worst imaginable scar). Total scores range from 6 to 60, with lower scores indicating better quality.
From surgery to 24 months, assessed every 3 months
Soft tissue reconstruction
時間枠:perioperative period
Soft tissue reconstruction will be recorded as whether the patient required additional soft tissue reconstruction procedures (e.g., skin grafting) during surgery.
perioperative period
Total surgical duration
時間枠:During the operative procedure
The time elapsed from the first incision to the completion of wound closure, measured in minutes.
During the operative procedure
Biopsy diagnostic accuracy
時間枠:perioperative period
Diagnostic accuracy was defined as the percentage of participants whose percutaneous biopsy results are concordant with the final histopathological diagnosis from the surgical specimen. This is a binary outcome.
perioperative period
Metastasis free survival (MFS)
時間枠:From surgery to 24 months, assessed every 6 months
Metastasis-free survival is defined as the time from definitive surgery to the first radiologically confirmed distant metastasis (e.g., lung, bone, or other organs). Metastasis will be assessed using scheduled chest CT scans and other imaging as clinically indicated. Participants without metastasis will be censored at their last follow-up visit.
From surgery to 24 months, assessed every 6 months
The Toronto Extremity Salvage Score
時間枠:From surgery to 24 months, assessed every 3 months
The Toronto Extremity Salvage Score (TESS) is a patient-reported outcome measure (PROM) specifically designed to evaluate the physical function of individuals who have undergone limb-salvage surgery for bone or soft-tissue sarcomas.The raw score is converted into a percentage ranging from 0 to 100. Higher score indicates better function.
From surgery to 24 months, assessed every 3 months
Overall survival (OS)
時間枠:From surgery to 24 months, assessed every 3 months
Overall survival is defined as the time from definitive surgery to death from any cause. Participants alive at last follow-up will be censored. Survival status will be assessed at each scheduled visit.
From surgery to 24 months, assessed every 3 months
Need for re-biopsy
時間枠:preoperative period
Number of participants requiring more than one biopsy procedure to obtain a definitive diagnostic result.
preoperative period
Request for external pathology consultation
時間枠:perioperative period
Number of participants for whom a second opinion from an external pathology department was sought to confirm the primary diagnosis.
perioperative period
intraoperative blood loss
時間枠:During the surgical procedure
Total volume of blood lost during the surgical procedure, measured in milliliters (mL).
During the surgical procedure
length of hospital stay
時間枠:perioperative period
The total number of days from the date of admission to the date of hospital discharge. This is a continuous outcome
perioperative period
Major wound complications
時間枠:Assessed from the date of surgery to 120 days after surgery.

Major wound complication was defined according to the O' sullivian et al (the Lancet, 2002). They are defined as a secondary operation under general or regional anaesthesia for wound repair (debridement, operative drainage, and secondary wound closure including rotationplasty, free flaps, or skin grafts),or wound management without secondary operation.

Wound management included an invasive procedure without general or regional anaesthesia (mainly aspiration of seroma), readmission for wound care such as intravenous antibiotics, or persistent deep packing for 120 days or longer. It will be recorded as binary outcome

Assessed from the date of surgery to 120 days after surgery.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2031年12月1日

研究の完了 (推定)

2033年12月1日

試験登録日

最初に提出

2026年4月2日

QC基準を満たした最初の提出物

2026年5月4日

最初の投稿 (実際)

2026年5月8日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月14日

QC基準を満たした最後の更新が送信されました

2026年7月12日

最終確認日

2025年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • LN_Biopsy_2025

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する